

JC037 d PCT/PTO 17 OCT 2005

PTO/SB-47 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

180

Application Number

10/520,477

Filing Date

January 4, 2005

First Named Inventor

Patrick McGowan

Art Unit

Examiner Name

Attorney Docket Number

014875-000002

ENCLOSURES (check all that apply)☐ Fee Transmittal Form☐ Fee Attached☐ Amendment / Reply☐ After Final☐ Affidavits/declaration(s)☐ Extension of Time Request☐ Express Abandonment Request☒ Information Disclosure Statement☐ Certified Copy of Priority Documents☐ Response to Missing Parts/
Incomplete Application☐ Response to Missing Parts
under 37 CFR 1.52 or 1.53☐ Drawing(s)☐ Licensing-related Papers☐ Petition☐ Petition to Convert to a
Provisional Application☐ Power of Attorney, Revocation
Change of Correspondence
Address☐ Terminal Disclaimer☐ Request for Refund☐ CD, Number of CD(s) _____☐ Landscape Table on CD☐ After Allowance Communication to Group☐ Appeal Communication to Board
of Appeals and Interferences☐ Appeal Communication to Group
(Appeal Notice, Brief, Reply Brief)☐ Proprietary Information☐ Status Letter☒ Other Enclosure(s) (please identify
below):Copies of 5 foreign references and 10
publication documents;
Acknowledgement Postcard

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name

MOORE & VAN ALLEN

Signature

Printed Name

WILLIAM A. BARRETT

Date

October 14, 2005

Reg. No.

42,296

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Signature

Typed or printed name

Katrina Holland

Date

October 14, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Patrick McGowan, et al.

Group Art Unit:

Serial Number: 10/520,477

Examiner:

Filed: January 4, 2005

For: FUNCTIONALIZED METALLOCENES AS ANTICANCER DRUGS


Mail Stop Amendment
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Customer No.: 24,239

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.56 AND 37 C.F.R. § 1.97**

It is respectfully requested that the documents listed on the attached Forms PTO/SB/08a and PTO/SB/08b be considered by the Patent and Trademark Office in the above-referenced application and made of record therein. Full text copies of the relevant documents are enclosed. This information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last.


Respectfully submitted,

By: 
William A. Barrett
Registration No. 42,296
Attorney for Applicants
Moore & Van Allen, PLLC
Phone: 919-286-8000
Facsimile: 919-286-8199

October 14, 2005
Date

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the US Postal Service as first class mail on October 14, 2005, in an envelope addressed to Commissioner of Patents, PO Box 1450, Alexandria, VA 22313-1450


Katrina Holland



Approved for use through 07/31/2006 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/520,477
Filing Date	January 4, 2005
First Named Inventor	Patrick McGowan
Art Unit	
Examiner Name	
Attorney Docket Number	014875-000002

Sheet	1	of	2	Attorney Docket Number	014875-000002
-------	---	----	---	------------------------	---------------

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials'	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	A3	WO 01/42260 A1	06/14/2001	University of Leeds		
	A4	WO 94/04142	03/03/1994	Ehud Keinan		
	A5	DE 41 35 292 A 1	05/14/1992	Usui Kokusai Sangyo Kaisha Ltd.		
	A6	EP 0 202 673 A3	11/26/1986	Köpf-Maier, et al.		
	A7	EP 0 202 673 A2	11/26/1986	Köpf		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/520,477		
		Filing Date	January 4, 2005		
		First Named Inventor	Patrick McGowan		
		Art Unit			
Examiner Name					
Sheet	2	of	2	Attorney Docket Number	014875-000002

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A8	PETER JUTZI et al.; Titanium and Zirconium Bent-Sandwich Complexes with the New [2-(Diisopropylamino)ethyl]cyclopentadienyl Ligand: Catalysts for the Polymerization of Ethylene and the Dehydrocoupling of Phenylsilane; Organometallics; 1996; 15, pp. 4153-4161; American Chemical Society	
	A9	PETER JUTZI et al.; Der(N,N-Dimethylaminoethyl)cyclopentadienyl-Ligand in der Komplexchemie von Titan und Zirkon; Journal of Organometallic Chemistry; 1995; 486, pp. 287-289; Elsevier Science S.A.	
	A10	P KÖPF-MAIER et al.; Organometallic titanium, vanadium, niobium, molybdenum and rhenium complexes-early transition metal antitumor drugs; Metal Compounds in Cancer Therapy; Chapter 6, pp. 109-146; Chapman & Hall, London	
	A11	PETRA KÖPF-MAIER, et al.; Vanadocen-dichlorid-ein weiteres Antitumor-Agens aus der Metallocenreihe; Z. Naturforsch; 1979; 34b, pp. 805-807	
	A12	MARGARET M. HARDING et al.; Antitumor Metallocenes: Structure-Activity Studies and interactions with Biomolecules; Current Medicinal Chemistry; 2000; 7, pp. 1289-1303; Bentham Science Publishers Ltd.	
	A13	CV CHRISTODOULOU et al.; Anti-proliferative activity and mechanism of action of titanocene dichloride; British Journal of Cancer; 1998; 77(12) pp. 2088-2097; Cancer Research Campaign	
	A14	JEFFREY H. TONEY et al.; Hydrolysis Chemistry of the Metallocene Dichlorides M(η^5 -C ₅ H ₅) ₂ Cl ₂ , M = Ti, V, Zr. Aqueous Kinetics, Equilibria, and Mechanistic Implications for a New Class of Antitumor Agents; J. Am. Chem. Soc.; 1985; 107, pp. 947-953; American Chemical Society	
	A15	ELIZABETH E. TRIMMER et al.; Cisplatin; Essays in Biochemistry; 1999; Vol. 34, Chapter 12, pp. 191-211; Department of Chemistry and Division of Bioengineering and Environmental Health, Massachusetts Institute of Technology	
	A16	JOHN M. VENDITTI; Preclinical Drug Development: Rationale and Methods; Seminars in Oncology; 1981; Vol. 8, No. 4, pp. 349-361; Drug Evaluation Branch, Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, Bethesda, MD	
	A17	M. SATYA MARTHY et al.; Antitumor and Toxicologic Properties of the Organometallic Anticancer Agent Vanadocene Dichloride; Inorganica Chimica Acta; 1988; 152, pp. 117-124; Elsevier Sequoia	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.